Magdy ElSharkawy
Ain Shams University, Egypt
Posters-Accepted Abstracts: J Diabetes Metab
Poor glycemic control is a predictor of mortality in diabetic dialysis patients. HbA1c is regarded as the gold standard for measurement of glycemic control and is invaluable in the treatment of diabetic patients. Both the (DCCT and UKPDS), showed that maintaining blood glucose at normal or near-normal levels can reduce many diabetic complications. However both trials excluded end stage renal disease patients (CKD 4 and 5) from the study population. And most patients as well as doctors consider that diabetic patients with advanced renal disease are less likely to develop hyperglycemia. Aim of the study is to evaluate diabetic control using HbA1c in type 2 diabetic patients with; CKD 4, and in diabetic dialysis patients. Patients and methods: 100 type 2 diabetic patients were divided into 2 groups; group I (G I); 50 dialysis diabetic patients, and group II (G II); 50 CKD 4 diabetic patients. Forall patients�?? wemeasured fasting (FBS) and post-prandial blood sugar (PPBS), HbA1c,s cholesterol, s. albumin. Results: using the cut off valueof HbA1c of<7, 50 % of G I and 24% of G II had poor diabeticcontrol. Hemodialysis group had significantly lower HbA1c level (7.328 ± 0.972) the predialysis group (8.598 ± 1.31); (p=0.0001). HbA1c level wasstrongly correlated with FBS and PPBS levels and with duration of diabetesillness (r= 0.71, 0.69 and 0.62, 0.7 in G I and G II, and with duration (r=0.42)). Patients with poor glycemic control had longer diabetes duration thancases with good control. Conclusion: poor glycemic control iscommon in dialysis as well as CKD 4 patients and is strongly related to durationof diabetes. This necessitates proper control of diabetes in those patients toprevent complications. HbA1c can be used as a good tool in predictionof glycemic control in dialysis as well as CKD 4 patients.
Email: magdi35@hotmail.com
